6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

L.Paz-Ares; M.N.Pollak; P.D.Eisenberg; L.J.Blakely; P.Haluska; R.B.Cohen; H.Kreisman; C.Melvin; A.Gualberto; D.Karp

首页> 外文期刊>European Journal of Cancer Supplements >6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

【24h】

6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

机译：6508 ORAL CP-751，871，一种抗IGF-1R抗体，与紫杉醇和卡铂或紫杉醇和卡铂一起作为晚期非小细胞肺癌（NSCLC）的一线治疗：Ib期/随机期二，非比较，开放标签试用

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements 》 |2007年第4期| 共2页
作者
L.Paz-Ares; M.N.Pollak; P.D.Eisenberg; L.J.Blakely; P.Haluska; R.B.Cohen; H.Kreisman; C.Melvin; A.Gualberto; D.Karp;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC) [J] . Roger B. Cohen, Corey J. Langer, George Rajan Simon, Cancer Chemotherapy and Pharmacology . 2007 ,第1期

机译：CP-547,632联合紫杉醇和卡铂或单独使用紫杉醇和卡铂作为晚期非小细胞肺癌（NSCLC）的一线治疗的I期/随机II期，非比较，多中心，开放标签试验
2. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer [J] . LangerC.J., OlszanskiA.J., KarpD.D., Journal of Clinical Oncology . 2014 ,第19期

机译：晚期非小细胞肺癌一线非那妥单抗联合紫杉醇和卡铂与单独使用紫杉醇和卡铂的III期随机试验
3. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer [J] . LangerC.J., OlszanskiA.J., KarpD.D., Journal of Clinical Oncology . 2014 ,第19期

机译：晚期非小细胞肺癌一线非那妥单抗联合紫杉醇和卡铂与单独使用紫杉醇和卡铂的III期随机试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Randomized Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer [O] . Corey J. Langer, Silvia Novello, Keunchil Park, -1

机译：一线非格单抗联合紫杉醇和卡铂与单独使用紫杉醇和卡铂治疗晚期非小细胞肺癌的随机III期试验
6. P3-135: Results of an open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC) [O] . Reynolds Craig, Barrera David, Vu Duy Quoc, 2007

机译：P3-135：针对晚期非鳞状非小细胞肺癌（NSCLC）患者的一线治疗纳米粒结合白蛋白的紫杉醇（nab-紫杉醇），卡铂和贝伐单抗的开放式II期试验的结果

6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

著录项

相似文献

相关主题

期刊订阅